Phase 1b/2a Trial of CNP-103 for Stage 3 Type 1 Diabetes Initiated
COUR Pharmaceutical has initiated Phase 1b/2a clinical trial for CNP-103 in adolescents and adults with recently diagnosed Stage 3 Type 1 Diabetes.
Asset / Drug
Drug and asset intelligence for CNP-103 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.